期刊
SURGICAL ONCOLOGY CLINICS OF NORTH AMERICA
卷 26, 期 4, 页码 791-+出版社
W B SAUNDERS CO-ELSEVIER INC
DOI: 10.1016/j.soc.2017.05.014
关键词
Basket clinical trial; Biomarker; Molecular profiling
资金
- NCI NIH HHS [R01 CA188430] Funding Source: Medline
The design of modern oncology clinical trials seeks to match patients' cancer molecular biomarkers with medications that specifically target those biomarkers, a general paradigm shift in cancer care coined clinical cancer biology. This approach exploits the synthetic lethality between a specific genetic alteration in the cancer cell and a drug: rapid termination of exaggerated kinase activity exemplifies this phenomenon. Synthetic lethality based investigations are driven by rapidly evolving technologies for cancer molecular profiling. As these technologies evolve, future clinical trials will test drugs' activity based on the molecular mechanisms rather than by the tumor's appearance under a microscope.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据